SLNO Quote, Financials, Valuation and Earnings

Axsome Therapeutics has a net margin of -- compared to Soleno Therapeutics's net margin of -63.08%. Soleno Therapeutics's return on equity of -- beat Axsome Therapeutics's return on equity of -244.32%.

Soleno Therapeutics has a consensus price target of $102.13, signalling upside risk potential of 46.04%. On the other hand Axsome Therapeutics has an analysts' consensus of $177.35 which suggests that it could grow by 69.77%. Given that Axsome Therapeutics has higher upside potential than Soleno Therapeutics, analysts believe Axsome Therapeutics is more attractive than Soleno Therapeutics.

Soleno Therapeutics has a beta of -2.285, which suggesting that the stock is 328.466% less volatile than S&P 500. In comparison Axsome Therapeutics has a beta of 0.883, suggesting its less volatile than the S&P 500 by 11.73%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Axsome Therapeutics pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than Axsome Therapeutics quarterly revenues of $118.8M. Soleno Therapeutics's net income of -$56M is higher than Axsome Therapeutics's net income of -$74.9M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Axsome Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,589.44x versus 12.98x for Axsome Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Legend Biotech has a net margin of -- compared to Soleno Therapeutics's net margin of 14.09%. Soleno Therapeutics's return on equity of -- beat Legend Biotech's return on equity of -15.44%.

Soleno Therapeutics has a consensus price target of $102.13, signalling upside risk potential of 46.04%. On the other hand Legend Biotech has an analysts' consensus of $77.99 which suggests that it could grow by 133.09%. Given that Legend Biotech has higher upside potential than Soleno Therapeutics, analysts believe Legend Biotech is more attractive than Soleno Therapeutics.

Soleno Therapeutics has a beta of -2.285, which suggesting that the stock is 328.466% less volatile than S&P 500. In comparison Legend Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Legend Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Legend Biotech pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than Legend Biotech quarterly revenues of $186.5M. Soleno Therapeutics's net income of -$56M is lower than Legend Biotech's net income of $26.3M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Legend Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,589.44x versus 9.75x for Legend Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of -- compared to Soleno Therapeutics's net margin of -57.51%. Soleno Therapeutics's return on equity of -- beat Madrigal Pharmaceuticals's return on equity of -63.91%.

Soleno Therapeutics has a consensus price target of $102.13, signalling upside risk potential of 46.04%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $414.07 which suggests that it could grow by 34.53%. Given that Soleno Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Soleno Therapeutics is more attractive than Madrigal Pharmaceuticals.

Soleno Therapeutics has a beta of -2.285, which suggesting that the stock is 328.466% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.683, suggesting its less volatile than the S&P 500 by 168.299%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $103.3M. Soleno Therapeutics's net income of -$56M is higher than Madrigal Pharmaceuticals's net income of -$59.4M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,589.44x versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Neurocrine Biosciences has a net margin of -- compared to Soleno Therapeutics's net margin of 16.43%. Soleno Therapeutics's return on equity of -- beat Neurocrine Biosciences's return on equity of 13.72%.

Soleno Therapeutics has a consensus price target of $102.13, signalling upside risk potential of 46.04%. On the other hand Neurocrine Biosciences has an analysts' consensus of $160.09 which suggests that it could grow by 59.93%. Given that Neurocrine Biosciences has higher upside potential than Soleno Therapeutics, analysts believe Neurocrine Biosciences is more attractive than Soleno Therapeutics.

Soleno Therapeutics has a beta of -2.285, which suggesting that the stock is 328.466% less volatile than S&P 500. In comparison Neurocrine Biosciences has a beta of 0.334, suggesting its less volatile than the S&P 500 by 66.575%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neurocrine Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Neurocrine Biosciences pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than Neurocrine Biosciences quarterly revenues of $627.7M. Soleno Therapeutics's net income of -$56M is lower than Neurocrine Biosciences's net income of $103.1M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Neurocrine Biosciences's PE ratio is 30.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,589.44x versus 4.41x for Neurocrine Biosciences. Usually stocks with elevated PS ratios are considered overvalued.